Acadesine:一种新药在冠状动脉旁路移植可以改善心肌保护。第一个国际多中心研究的结果。跨国Acadesine研究小组。
文章的细节
-
引用
复制到剪贴板 -
杰米逊Menasche P, WR, Flameng W,戴维斯可
Acadesine:一种新药在冠状动脉旁路移植可以改善心肌保护。第一个国际多中心研究的结果。跨国Acadesine研究小组。
J Thorac Cardiovasc Surg. 1995年10月,110 (4 Pt 1): 1096 - 106。
- PubMed ID
-
7475138 (在PubMed]
- 文摘
-
acadesine的影响,adenosine-regulating代理,在心肌梗塞的发生率,所有不良心血管结果(心肌梗死、心脏猝死、左心室功能障碍,危及生命的心律失常,或脑血管意外)和死亡率在821年评估患者接受冠状动脉旁路移植。患者前瞻性分层高危人群(年龄> 70岁、不稳定心绞痛、以前的冠状动脉旁路手术,不成功的血管成形术,射血分数< 30%)或non-high-risk组。他们随机双盲的方式安慰剂(n = 418)或acadesine (n = 403)通过静脉输液7小时(每分钟0.1毫克/公斤)和cardioplegic解决方案(安慰剂或acadesine;5微克/毫升)。Acadesine没有明显影响心肌梗死的发生率在整个研究人口,但显著降低q波性心肌梗死的发生率在高危患者(安慰剂,19.7%;acadesine, 10.0%;p = 0.032)。所有不良心血管结果的发生率(安慰剂,19.4%;acadesine, 18.4%)和总体死亡率(安慰剂,3.4%;acadesine,两治疗组2.7%)相似。 However, acadesine reduced the incidence of cardiac related events that contributed to deaths occurring during the first 3 postoperative days so that the incidence of death in this period was lower (placebo, 1.9%; acadesine, 0.2%; p = 0.038). No adverse events were related to acadesine treatment. Although overall there were no statistically significant between-group differences for the primary study end points, a secondary analysis in a prospectively defined high-risk subgroup suggests that acadesine may be beneficial in some patients.
DrugBank数据引用了这篇文章
- 药物